Menu
1 min read · estimated
APPROVED USE
What FDA approved
Extends the accelerated-phase Philadelphia chromosome-positive chronic myeloid leukemia indication to children age 1 and older with resistance or intolerance to prior treatment.
LAMPGEN ANALYSIS
Why it matters
The decision covers a pediatric advanced-phase population beyond the existing chronic-phase pediatric use.
What research teams should watch
Verify disease phase, prior tyrosine kinase inhibitor response and pediatric dose calculation.
PRIMARY RECORDS